BiotechTube

AMG 334

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Post-Traumatic Headache

Conditions

Post-Traumatic Headache, Mild Traumatic Brain Injury, Post-Concussion Syndrome

Trial Timeline

Apr 5, 2019 → Dec 31, 2019

NCT ID
NCT03974360

About AMG 334

AMG 334 is a phase 2 stage product being developed by Novartis for Post-Traumatic Headache. The current trial status is completed. This product is registered under clinical trial identifier NCT03974360. Target conditions include Post-Traumatic Headache, Mild Traumatic Brain Injury, Post-Concussion Syndrome.

What happened to similar drugs?

3 of 7 similar drugs in Post-Traumatic Headache were approved

Approved (3) Terminated (3) Active (1)
✅Galcanezumab-GnlmEli LillyApproved
🔄Quetiapine Fumarate + quetiapine fumarate placeboAstraZenecaPhase 3
❌Zoloft (Sertraline)PfizerPhase 3
❌Levetiracetam + PlaceboUCBPhase 3
❌Placebo + BrexpiprazoleLundbeckPhase 3
✅AbobotulinumtoxinA + Normal salineIpsenApproved
✅Tramadol + PlaceboBrain BiotechApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04419259Phase 2UNKNOWN
NCT03974360Phase 2Completed

Competing Products

16 competing products in Post-Traumatic Headache

See all competitors
ProductCompanyStageHype Score
Galcanezumab-GnlmEli LillyApproved
43
Quetiapine Fumarate + quetiapine fumarate placeboAstraZenecaPhase 3
40
Rizatriptan + PlaceboMerckPre-clinical
18
Balovaptan + PlaceboRochePhase 2
35
ErenumabAmgenPhase 2
35
PF-04457845 + PlaceboPfizerPhase 2
27
Zoloft (Sertraline)PfizerPhase 3
32
Levetiracetam + PlaceboUCBPhase 3
32
levetiracetam + Placebo + LevetriracetamUCBPhase 2/3
38
Placebo + BrexpiprazoleLundbeckPhase 3
29
Brexpiprazole + Sertraline + Brexpiprazole Matching Placebo + Sertraline Matching PlaceboLundbeckPhase 2
32
AbobotulinumtoxinA + Normal salineIpsenApproved
40
Nabiximols + PlaceboJazz PharmaceuticalsPhase 2/3
27
60 mg PRAX-114 or 40 mg PRAX-114 + Placebo + 40 mg PRAX-114Praxis Precision MedicinesPhase 2
24
MDMANautilus BiotechnologyPhase 2
50
Tramadol + PlaceboBrain BiotechApproved
33